

UNITED STATES PATENT AND TRADEMARK OFFICE



UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/938,275	08/22/2001	Gerardo Castillo	PROTEO.P03	1974
7590 06/22/2005		EXAMINER		
PATRICK M. DWYER PROTEOTECH, INC. SUITE 114 1818 WESTLAKE AVENUE SEATTLE, WA 98109			CHERNYSHEV, OLGA N	
			ART UNIT	PAPER NUMBER
			1646	
			DATE MAILED: 06/22/2005	

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)			
Office Action Commons	09/938,275	CASTILLO ET AL.			
Office Action Summary	Examiner	Art Unit			
	Olga N. Chernyshev	1646			
The MAILING DATE of this communication app Period for Reply	ears on the cover sheet with the	correspondence address			
A SHORTENED STATUTORY PERIOD FOR REPLY THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.13 after SIX (6) MONTHS from the mailing date of this communication. - If the period for reply specified above is less than thirty (30) days, a reply if NO period for reply is specified above, the maximum statutory period was Failure to reply within the set or extended period for reply will, by statute, Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b).	6(a). In no event, however, may a reply be ti within the statutory minimum of thirty (30) da ill apply and will expire SIX (6) MONTHS fror cause the application to become ABANDON	mely filed ys will be considered timely. n the mailing date of this communication. ED (35 U.S.C. § 133).			
Status					
1) Responsive to communication(s) filed on					
	action is non-final.				
3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.					
Disposition of Claims					
 4) Claim(s) 1,4,5,11,12,15,19-22 and 27 is/are pending in the application. 4a) Of the above claim(s) is/are withdrawn from consideration. 5) Claim(s) is/are allowed. 6) Claim(s) 1, 4, 5, 11, 12, 15, 19-22 and 27 is/are rejected. 7) Claim(s) is/are objected to. 8) Claim(s) are subject to restriction and/or election requirement. 					
Application Papers					
9) The specification is objected to by the Examiner.					
10)☐ The drawing(s) filed on is/are: a)☐ accepted or b)☐ objected to by the Examiner.					
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).					
Replacement drawing sheet(s) including the correction 11) The oath or declaration is objected to by the Ex	,				
Priority under 35 U.S.C. § 119					
12) Acknowledgment is made of a claim for foreign a) All b) Some * c) None of: 1. Certified copies of the priority documents 2. Certified copies of the priority documents 3. Copies of the certified copies of the priorical application from the International Bureau * See the attached detailed Office action for a list	s have been received. s have been received in Applica ity documents have been receiv ı (PCT Rule 17.2(a)).	tion No ved in this National Stage			
Attachment(s)					
1) Notice of References Cited (PTO-892)	4) Interview Summary (PTO-413) Paper No(s)/Mail Date				
Notice of Draftsperson's Patent Drawing Review (PTO-948) Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08) Paper No(s)/Mail Date		Patent Application (PTO-152)			

M

DETAILED ACTION

Response to Amendment

1. Claims 1, 5, 11, 15, 19 and 22 have been amended, claims 17-18 and 23-26 have been cancelled as requested in the amendment filed on May 09, 2005. Claims 1, 4, 5, 11, 12, 15, 19-22 and 27 are pending in the instant application.

Claims 1, 4, 5, 11, 12, 15, 19-22 and 27 are under examination in the instant office action.

- 2. The Text of those sections of Title 35, U.S. Code not included in this action can be found in a prior Office action.
- 3. Any objection or rejection of record, which is not expressly repeated in this action has been overcome by Applicant's response and withdrawn.

Formal metters

4. Applicant is advised that the amendment to the claims filed on May 09, 2005 remains in non-compliance for failure to meet the requirements of 37 CFR 1.121, as amended on June 30, 2003 (see 68 Fed. Reg. 38611, Jun. 30, 2003) with respect to proper status identifiers.

Specifically claims 4, 12, 20-21 and 27 are presented with status identifiers, which are not permissible under rule 37 CFR 1.121. Appropriate correction is required.

New grounds of rejection necessitated by amendment

Claim Rejections - 35 USC § 112

The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

Application/Control Number: 09/938,275

Art Unit: 1646

5. Claims 1, 4, 5, 11, 12, 15, 19-22 and 27 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

Page 3

- 6. Claims 1 and 15 are vague and indefinite for recitation "a cell-free system or an in vitro site containing beta-amyloid protein", which does not make sense. Applicant is advised that amendment of claims 1 and 15 obviated rejection under 35 U.S.C. 112, first paragraph (see reasons of record in section 7 of office action mailed on September 27, 2004), because it limited the claimed subject matter to *in vitro* cell-free conditions. However, claims 1 and 15, as currently amended, encompass limitation, which cannot be definitively interpreted. The metes and bounds of "cell-free system" cannot be determined from the claims or the instant specification, as filed. For example, by broadest reasonable interpretation, the claimed method encompasses administration of laminin to a jar containing pure Aβ protein. One skilled in the art readily appreciates that in that particular case, there would be no beta-amyloid protein fibril formation. Furthermore, it is not obvious what constitutes "an in vitro site containing beta-amyloid". Does the "an in vitro site containing beta-amyloid" also contain cells? Applicant is advised to rewrite the text of the claims to better express the claimed subject matter.
- 7. Claims 1, 15 and 19 are vague and ambiguous for recitation "effective amount" without stating an objective as what the amount is effective for.
- 8. Claims 5 and 22 are indefinite because association of formation of beta-amyloid fibrils within cell-free system, as recited in claim 1, from which claim 5 depends and Alzheimer's disease it is not obvious. Clarification is required.

Application/Control Number: 09/938,275 Page 4

Art Unit: 1646

9. Claim 15 is vague and ambiguous for recitation "any non *in vivo* site containing beta-amyloid". The metes and bounds of the limitation cannot be positively determined from the claim or the instant specification. See also reasoning in section 6 of the instant office action as applied to claims 1 and 15.

10. Claims 4, 11, 12, 20-21 and 27 are indefinite for being dependent from indefinite claims.

Conclusion

- 11. No claim is allowed.
- 12. Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, **THIS ACTION IS MADE FINAL**. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the date of this final action.

Art Unit: 1646

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Olga N. Chernyshev whose telephone number is (571) 272-0870. The examiner can normally be reached on 8:00 AM to 5:00 PM.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Anthony C. Caputa can be reached on (571) 272-0829. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Certain papers related to this application may be submitted to Technology Center 1600 by facsimile transmission. Papers should be faxed to Technology Center 1600 via the PTO Fax center located in Crystal Mall 1 (CM1). The faxing of such papers must conform with the notices published in the Official Gazette, 1156 OG 61 (November 16, 1993) and 1157 OG 94 (December 28, 1993) (see 37 C.F.R. § 1.6(d)). NOTE: If Applicant *does* submit a paper by fax, the original signed copy should be retained by Applicant or Applicant's representative. NO DUPLICATE COPIES SHOULD BE SUBMITTED so as to avoid the processing of duplicate papers.

Official papers filed by fax should be directed to (703) 872-9306. If this number is out of service, please call the Group receptionist for an alternative number. Faxed draft or informal communications with the examiner should be directed to (571) 273-0870. Official papers should NOT be faxed to (571) 273-0870.

Application/Control Number: 09/938,275

Art Unit: 1646

Page 6

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Olga N. Chernyshev, Ph.D.

Primary Examiner Art Unit 1646

June 17, 2005